Nordic Life Science 1
Your Preferred Partner in Europe Intellectual pro
perty rights – A business opportunity Patents • Trademarks • Design • Domain Names Legal Services • Post-grant / Enforcement Strategic Counselling • Annuities & Renewals Since 1894 Jacob Tolstrup, EVP Commercial Operations, Lundbeck NEW MA RK E T Lundbeck and Takeda have jointly announced that the MHLW of Japan has approved Trintellix for the treatment of depression and depressed state. HE NDA FILING submitted to the MHLW in September 2018 included data from a phase III trial, which demonstrated statistically significant improvement in overall symptoms of depression in adults compared to placebo. The regulatory submission also featured data from three other studies conducted globally and in Japan. This study was conducted as a randomized, placebocontrolled, double-blind, parallel-group trial in 493 adult patients in Japan with recurrent depression. Patients were randomly assigned to a vortioxetine 10mg, 20mg, or placebo group. The primary endpoint was change in total score from baseline (at the onset of double-blinding) on the Montgomery-Åsberg Depression Rating Scale (MADRS) by week 8 of administration compared to placebo. The study demonstrated positive results of vortioxetine, including the primary endpoint as compared to placebo for the treatment of MDD in adults. “The approval of Trintellix represents a new chapter in Lundbeck’s commercial expansion, as we will have our own commercial organization behind the launch of Trintellix in Japan in collaboration with our partner Takeda,” says Jacob Tolstrup, EVP Commercial Operations, Lundbeck. ANETTE ROMARE M.Sc. Chem. Eng. & Biotechnology European Patent Attorney Anette has a chemical background with particular expertise in absorbent products. She has vast experience of EPO opposition and appeal proceedings as well as patent evaluations and opinions. www.valea.eu